AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 175 filers reported holding AKERO THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $33,645,839 | -7.1% | 1,434,179 | 0.0% | 2.71% | +35.0% |
| Q1 2024 | $36,227,362 | -19.3% | 1,434,179 | -25.4% | 2.01% | -22.4% |
| Q4 2023 | $44,917,788 | -27.3% | 1,923,674 | +57.5% | 2.59% | -17.8% |
| Q3 2023 | $61,792,271 | +10.1% | 1,221,674 | +1.7% | 3.15% | +3.9% |
| Q2 2023 | $56,102,284 | +13.7% | 1,201,591 | -6.8% | 3.03% | +55.5% |
| Q1 2023 | $49,339,752 | -49.9% | 1,289,591 | -28.2% | 1.95% | -55.2% |
| Q4 2022 | $98,388,194 | +32.9% | 1,795,405 | -17.5% | 4.36% | -4.7% |
| Q3 2022 | $74,057,000 | +316.2% | 2,174,946 | +15.5% | 4.57% | +349.6% |
| Q2 2022 | $17,792,000 | -19.3% | 1,882,698 | +21.2% | 1.02% | +1.1% |
| Q1 2022 | $22,037,000 | -32.8% | 1,552,990 | +0.1% | 1.01% | -39.9% |
| Q4 2021 | $32,806,000 | -3.5% | 1,551,090 | +2.0% | 1.67% | 0.0% |
| Q3 2021 | $33,999,000 | -8.6% | 1,521,190 | +1.5% | 1.67% | +11.8% |
| Q2 2021 | $37,189,000 | +377.8% | 1,498,938 | +458.7% | 1.50% | +324.1% |
| Q1 2021 | $7,783,000 | – | 268,282 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 103,816 | $5,251,013 | 6.02% |
| Boxer Capital, LLC | 1,676,733 | $84,809,155 | 4.52% |
| Redmile Group, LLC | 1,769,684 | $89,510,617 | 4.26% |
| Ghost Tree Capital, LLC | 250,000 | $12,645,000 | 4.16% |
| Logos Global Management LP | 600,000 | $30,348,000 | 4.05% |
| COMMODORE CAPITAL LP | 565,000 | $28,577,700 | 3.34% |
| Yiheng Capital Management, L.P. | 1,221,674 | $61,792,271 | 3.15% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,116,000 | 3.07% |
| Atlas Venture Life Science Advisors, LLC | 359,251 | $18,170,915 | 2.81% |
| Perceptive Advisors | 1,619,425 | $81,910,517 | 2.73% |